Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:35:20 EDT Tue 13 May 2025
Enter Symbol
or Name
USA
CA



Q:MNOV - MEDICINOVA INC - https://www.medicinova.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNOV - Q0.21.30·2.140.11.4398-0.0302-2.16.58591.47  1.48  1.42682.55  1.1216:05:06Apr 1415 min RT 2¢

Recent Trades - Last 10 of 59
Time ETExPriceChangeVolume
16:05:06Q1.45-0.021
16:00:01Q1.45-0.0237
16:00:01Q1.45-0.0210
15:59:51Q1.45-0.026
15:59:51Q1.45-0.021
15:57:17Q1.445-0.02518
15:50:19Q1.47 2
15:38:00Q1.46-0.011
15:19:45Q1.45-0.021
15:12:46Q1.45-0.0268

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-04-14 19:00U:MNOVNews ReleaseMediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025
2025-04-08 19:00U:MNOVNews ReleaseFirst Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
2024-12-05 18:00U:MNOVNews ReleaseMediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
2024-11-19 09:00U:MNOVNews ReleaseMediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
2024-11-14 18:00U:MNOVNews ReleaseMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
2024-11-11 18:00U:MNOVNews ReleaseMediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
2024-10-23 19:00U:MNOVNews ReleaseMediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
2024-09-30 09:00U:MNOVNews ReleaseMediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
2024-09-09 19:00U:MNOVNews ReleaseMediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
2024-09-03 19:00U:MNOVNews ReleaseMediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
2024-08-29 19:00U:MNOVNews ReleaseMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
2024-06-20 06:00U:MNOVNews ReleaseMediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
2024-06-05 06:00U:MNOVNews ReleaseMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
2024-06-03 06:00U:MNOVNews ReleaseMediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
2024-05-28 06:00U:MNOVNews ReleaseMediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
2024-05-20 06:00U:MNOVNews ReleaseMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
2024-05-14 06:00U:MNOVNews ReleaseMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome